Scarica l'app Stockscreener
12.17
7.70%
0.87
Pre-mercato:
11.39
-0.78
-6.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Novocure Ltd Borsa (NVCR) Ultime notizie
Is NovoCure’s (NVCR) Leadership Consolidation Clarifying Its Innovation Strategy Or Complicating Governance Signals? - simplywall.st
NovoCure Ltd (NVCR) Stock Up 5.4% and Still Undervalued -- GF Sc - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative - simplywall.st
NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist - Sahm
NovoCure Ltd (NVCR) Stock Down 3.8% -- Now Undervalued? GF Score: 66/100 - GuruFocus
NovoCure Limited Increases Compensation for Dr. Uri Weinberg Upon Appointment as Chief Medical Officer - Minichart
Novocure increases executive compensation as Uri Weinberg takes on dual roles By Investing.com - Investing.com South Africa
Novocure increases executive compensation as Uri Weinberg takes on dual roles - Investing.com
NovoCure appoints Uri Weinberg as Chief Medical Officer alongside Chief Innovation Officer - TradingView — Track All Markets
NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties - Stock Titan
NovoCure (BSP:N2VC34) Net Investment Income - GuruFocus
NovoCure (BSP:N2VC34) Other Assets for Insurance Companies - GuruFocus
NovoCure (BSP:N2VC34) Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Net Income (Loss) : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 6-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow from Discontinued Operations : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PEG Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Gross-Profit-to-Asset % : 49.36% (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Shiller PE Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Investment : R$-4,539 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Operating Income : R$-851 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 3-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Investments And Advances : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 1-Year Sharpe Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Retained Earnings : R$-7,040 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Interest and Commission Paid - GuruFocus
NovoCure (BSP:N2VC34) Inventories, Other : R$-0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Forward Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Graham Number : R$N/A (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PE Ratio (TTM) : At Loss (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted PS Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Long-Term Liabilities : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Other Current Assets : R$106 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Gross Property, Plant and Equipment : R$1,180 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Operating Expense : R$3,550 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Dividend Payout Ratio : 0.00 (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted Price-to-FCF : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Net Policyholder Benefits/Claims - GuruFocus
NovoCure (BSP:N2VC34) Policyholder Funds - GuruFocus
BSP:N2VC34 EBITDA: R$-581 Mil | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Goodwill : R$0 Mil (As of Dec. 2025) - GuruFocus
BSP:N2VC34 OCF Yield %: -3.95 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Other Operating Expense : R$-0 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:N2VC34 EV-to-EBITDA: 0.72 | Possible Value Trap - GuruFocus
BSP:N2VC34 Accounts Payable: R$667 Mil | Possible Value Trap - GuruFocus
BSP:N2VC34 FCF Margin %: -13.13% | Possible Value Trap - GuruFocus
NovoCure Ltd (BSP:N2VC34) DCF Valuation - GuruFocus
NovoCure Ltd (BSP:N2VC34) Dividend - GuruFocus
NovoCure (BSP:N2VC34) Net Issuance of Preferred Stock : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Fees and Other Income - GuruFocus
BSP:N2VC34 Total Payout Ratio: 0.02 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Net Loan - GuruFocus
NovoCure (BSP:N2VC34) Cash from Discontinued Operating Acti - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Property, Plant, Equipment : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Tax Payable : R$0 Mil (As of Dec. 2025) - GuruFocus
BSP:N2VC34 Tax Provision: R$-1 Mil | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Gross Loan - GuruFocus
NovoCure (BSP:N2VC34) Payments to Suppliers for Goods and S - GuruFocus
NovoCure (BSP:N2VC34) Marketable Securities : R$1,932 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow for Dividends : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 09, 2026) - GuruFocus
BSP:N2VC34 EBITDA per Share: R$-5.22 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Price-to-Owner-Earnings : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Stockholders Equity : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Change In Prepaid Assets : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Degree of Operating Leverage : -0.16 (As of Dec. 2025) - GuruFocus
2.40%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):